Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.78 |
| ▸ | QRFPR | Q96P65 | 4/20 | 0.55 |
| ▸ | FURIN | P09958 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536443 | 1.00 | OPRL1 (0.78) | OPRL1QRFPRFURIN | |
| SCHEMBL31536444 | 1.00 | OPRL1 (0.78) | OPRL1QRFPRFURIN | |
| SCHEMBL31536446 | 0.93 | OPRL1 (0.78) | OPRL1QRFPRFURIN | |
| SCHEMBL31536447 | 0.93 | OPRL1 (0.78) | OPRL1QRFPRFURIN | |
| SCHEMBL29355633 | 0.93 | OPRL1 (0.78) | OPRL1QRFPRFURIN | |
| Nociceptin-Nh2 SCHEMBL30033176 | 0.85 | OPRL1 (0.79) | OPRL1 | |
| SCHEMBL28918838 | 0.85 | OPRL1 (0.70) | OPRL1 | |
| Nociceptin SCHEMBL29358223 | 0.82 | OPRL1 (0.79) | OPRL1 | |
| SCHEMBL30130109 | 0.79 | TFPI (0.64) | OPRL1 | |
| SCHEMBL30980377 | 0.78 | OPRL1 (0.58) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115487289-A | Application of UFP-101 in preparing medicine for treating chronic heart failure | 山西医科大学第二医院 | 2022-12-20 | — | — | CN | claimed |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| CN-115487289-A | Application of UFP-101 in preparing medicine for treating chronic heart failure | 山西医科大学第二医院 | 2022-12-20 | — | — | CN | disclosed |
| CN-115487289-A | Application of UFP-101 in preparing medicine for treating chronic heart failure | 山西医科大学第二医院 | 2022-12-20 | — | — | CN | disclosed |
| CN-115487289-A | Application of UFP-101 in preparing medicine for treating chronic heart failure | 山西医科大学第二医院 | 2022-12-20 | — | — | CN | disclosed |
| EP-3759085-B1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| CN-111265663-B | Application of orphanin enkephalin receptor specific antagonist in preparation of arrhythmia treatment drug | 郭政 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | OPRL1, OPRK1, NOP56 | OPRL1 1/4885QRFPR 62/4885FURIN 3693/4885 |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885QRFPR 62/4885FURIN 3693/4885 |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | OPRL1, OPRK1, GAP43 | OPRL1 1/4885QRFPR 34/4885FURIN 2615/4885 |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885QRFPR 62/4885FURIN 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.